These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 15023581)

  • 21. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
    Fagan AM; Mintun MA; Mach RH; Lee SY; Dence CS; Shah AR; LaRossa GN; Spinner ML; Klunk WE; Mathis CA; DeKosky ST; Morris JC; Holtzman DM
    Ann Neurol; 2006 Mar; 59(3):512-9. PubMed ID: 16372280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
    Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
    Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.
    Jia JP; Meng R; Sun YX; Sun WJ; Ji XM; Jia LF
    Neurosci Lett; 2005 Jul 22-29; 383(1-2):12-6. PubMed ID: 15936505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid.
    Portelius E; Brinkmalm G; Tran A; Andreasson U; Zetterberg H; Westman-Brinkmalm A; Blennow K; Ohrfelt A
    Exp Neurol; 2010 Jun; 223(2):351-8. PubMed ID: 19559702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry.
    Portelius E; Tran AJ; Andreasson U; Persson R; Brinkmalm G; Zetterberg H; Blennow K; Westman-Brinkmalm A
    J Proteome Res; 2007 Nov; 6(11):4433-9. PubMed ID: 17927230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.
    Maddalena A; Papassotiropoulos A; Müller-Tillmanns B; Jung HH; Hegi T; Nitsch RM; Hock C
    Arch Neurol; 2003 Sep; 60(9):1202-6. PubMed ID: 12975284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
    J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No correlation between time-linked plasma and CSF Abeta levels.
    Le Bastard N; Aerts L; Leurs J; Blomme W; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Dec; 55(8):820-5. PubMed ID: 19695299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.
    Wiltfang J; Esselmann H; Bibl M; Hüll M; Hampel H; Kessler H; Frölich L; Schröder J; Peters O; Jessen F; Luckhaus C; Perneczky R; Jahn H; Fiszer M; Maler JM; Zimmermann R; Bruckmoser R; Kornhuber J; Lewczuk P
    J Neurochem; 2007 May; 101(4):1053-9. PubMed ID: 17254013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cerebrospinal fluid levels of beta-amyloid protein 1-42 in Alzhemier disease].
    Yi YX; Jian ZJ
    Hunan Yi Ke Da Xue Xue Bao; 2002 Apr; 27(2):171-2. PubMed ID: 12575353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
    Güntert A; Döbeli H; Bohrmann B
    Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
    Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype.
    Fagan AM; Younkin LH; Morris JC; Fryer JD; Cole TG; Younkin SG; Holtzman DM
    Ann Neurol; 2000 Aug; 48(2):201-10. PubMed ID: 10939571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.
    Iqbal K; Flory M; Khatoon S; Soininen H; Pirttila T; Lehtovirta M; Alafuzoff I; Blennow K; Andreasen N; Vanmechelen E; Grundke-Iqbal I
    Ann Neurol; 2005 Nov; 58(5):748-57. PubMed ID: 16247771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
    Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
    Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
    Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
    Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF.
    Rüetschi U; Zetterberg H; Podust VN; Gottfries J; Li S; Hviid Simonsen A; McGuire J; Karlsson M; Rymo L; Davies H; Minthon L; Blennow K
    Exp Neurol; 2005 Dec; 196(2):273-81. PubMed ID: 16154129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.